TCM Biotech International Corp. (TPEX:4169)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
51.30
+0.40 (0.79%)
May 13, 2025, 1:22 PM CST
-5.87%
Market Cap 3.03B
Revenue (ttm) 666.53M
Net Income (ttm) 21.01M
Shares Out 59.05M
EPS (ttm) 0.36
PE Ratio 142.50
Forward PE 25.65
Dividend 0.29 (0.56%)
Ex-Dividend Date n/a
Volume 34,208
Average Volume 41,429
Open 51.00
Previous Close 50.90
Day's Range 49.80 - 51.30
52-Week Range 43.65 - 63.60
Beta -0.20
RSI 43.87
Earnings Date Apr 18, 2025

About TCM Biotech International

TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for the prevention and treatment of liver diseases. The company’s products include osteoarthritis treatment products, osteoporosis treatment preparations, iron supplement, urinary system treatment products, expectorants/mucolytic agents, anti-hypertensive preparations, and anti-diabetic preparations, anti-adhesion systems, pellefeel wound care systems, Philips non-invasive ventilators, and others, as well as medical devices and functional foods.... [Read more]

Sector Healthcare
Founded 1998
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 4169
Full Company Profile

Financial Performance

In 2024, TCM Biotech International's revenue was 666.53 million, a decrease of -31.26% compared to the previous year's 969.62 million. Earnings were 21.01 million, an increase of 13.12%.

Financial Statements

News

There is no news available yet.